ARTICLE | Clinical News
Teva falls on Copaxone data
July 8, 2008 12:12 AM UTC
Teva (NASDAQ:TEVA) was off $4.02 to $43.18 on Monday after top-line data from the Phase III FORTE trial in 1,155 relapsing-remitting multiple sclerosis (RRMS) patients showed that the 40 mg dose of Co...